# Vortioxetine for Post-COVID-19 Condition

> **NCT05047952** · PHASE2 · COMPLETED · sponsor: **Brain and Cognition Discovery Foundation** · enrollment: 149 (actual)

## Conditions studied

- Post-COVID-19 Condition
- Post-COVID-19 Syndrome
- Cognitive Impairment

## Interventions

- **DRUG:** Vortioxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05047952
- **Lead sponsor:** Brain and Cognition Discovery Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-16
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05047952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05047952, "Vortioxetine for Post-COVID-19 Condition". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05047952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*